# Effect of self-monitoring of glucose in noninsulin treated patients with type two diabetes

Submission date 02/05/2007	<b>Recruitment status</b> No longer recruiting	[X] Prospectively registered [X] Protocol
<b>Registration date</b> 02/05/2007	<b>Overall study status</b> Completed	<ul> <li>[] Statistical analysis plan</li> <li>[X] Results</li> </ul>
Last Edited 29/12/2016	<b>Condition category</b> Nutritional, Metabolic, Endocrine	Individual participant data

### Plain English summary of protocol

Not provided at time of registration

## **Contact information**

**Type(s)** Scientific

**Contact name** Ms U.L. Malanda

#### **Contact details** VU Medical Centre Amsterdam EMGO-Instituut Afdeling Huisartsgeneeskunde Amsterdam Netherlands 1081 BT +31 (0)20 444 8395 u.malanda@vumc.nl

## Additional identifiers

EudraCT/CTIS number

**IRAS number** 

ClinicalTrials.gov number

Secondary identifying numbers NTR807

## Study information

### Scientific Title

The effect of self monitoring of blood glucose and urine glucose relative to usual care without self monitoring on diabetes related distress and glycaemic control in patients with type 2 diabetes who are not using insulin

### Acronym

IN CONTROL

### **Study objectives**

By applying self monitoring of glucose, patients with Diabetes Mellitus type two (DM2) may cope more independently with their disease. Self monitoring can aid in diabetes control by giving the patient the ability to make appropriate day-to-day treatment choices in diet and physical activity as well as in medication. Furthermore, it will improve a patient's recognition of hypoglycaemia or severe hyperglycaemia, and enhance patient empowerment regarding the effects of lifestyle and medication on glycaemic control and thereby provide a better perceived quality of life.

Please note that as of 26/10/2009 this trial was updated. All updates can be found under the relevant field with the above update date. The overall trial end date has been extended from 01 /07/2009.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

The ethics board of the VU Medical Centre, 22/11/2007

**Study design** Randomised active-controlled parallel-group trial

**Primary study design** Interventional

Secondary study design Randomised parallel trial

**Study setting(s)** Not specified

**Study type(s)** Treatment

### Participant information sheet

Health condition(s) or problem(s) studied Diabetes Mellitus type two (DM2)

#### Interventions

A stratified, randomised six-arm clinical trial among DM2 patients with an Hb1Ac of 7.0% or above who are not using insulin. Eligible and consenting subjects will be randomly assigned to the intervention groups Self Monitoring of Blood Glucose (SMBG) or Self Monitoring of Urine Glucose (SMUG), or to the control group.

Before randomisation the patients will be stratified according to treatment (i.e. using Sulphonylureas [SU] or not [Non-SU]). The SMBG and SMUG will be an integral part of a wider educational strategy; the intervention groups and the control group will receive a standardised treatment program to change their diet and lifestyle.

In addition, patients in the SMBG group will be educated to use the SMBG-device and patients in the SMUG-group will be educated to use the urine tests. They will learn to know and understand the ranges of test results and what steps to take in response to a high or low, or positive or negative reading.

The intervention groups will perform self-monitoring according to standard testing frequency instructions during one year.

### Intervention Type

Other

### Phase

Not Specified

### Primary outcome measure

1. Problem Areas In Diabetes scale (PAID) assessed at baseline and at 6 and 12 months after inclusion

2. Glycaemic control measured by glycated haemoglobin concentration (HbA1c-level) at baseline and at 6 and 12 months after inclusion

3. Cost-effectiveness assessed using cost-diaries and the European Quality of Life (EuroQoL) questionnaire

### Secondary outcome measures

- 1. Frequency and severity of hypoglycaemia
- 2. Change in well-being: 12-item Well Being Questionnaire (WBQ-12)
- 3. Patient satisfaction: Diabetes Treatment Satisfaction Questionnaire (DTSQ)
- 4. Changes in lifestyle factors:
- a. diet behaviour (Dutch Eating Behaviour Questionnaire [DEBQ])
- b. physical activity (Short Questionnaire to Assess Health enhancing physical activity [SQUASH])
- 5. Changes in medication use
- 6. Compliance
- 7. Medical care utilisation

All secondary outcomes will be assessed at baseline, 6 and 12 months after inclusion.

### Overall study start date

01/07/2007

### **Completion date**

01/11/2010

## Eligibility

### Key inclusion criteria

- 1. All patients are participants of the Diabetes Care System West-Friesland
- 2. Patients with type two diabetes with HbA1c levels of 7.0% or above who are not using insulin
- 3. Younger than 76 years
- 4. Known disease duration of over one year
- 5. Not used self monitoring of glucose in the previous year

### Participant type(s)

Patient

### Age group

Adult

**Sex** Both

**Target number of participants** 600

### Key exclusion criteria

- 1. Severe complications of diabetes
- 2. Pregnant women
- 3. Unable to carry out self monitoring of glucose
- 4. Unable to fill in questionnaires/diaries

### Date of first enrolment

01/07/2007

## Date of final enrolment

01/11/2009

## Locations

**Countries of recruitment** Netherlands

**Study participating centre VU Medical Centre Amsterdam** Amsterdam Netherlands 1081 BT

## Sponsor information

**Organisation** Vrije University Medical Centre (VUMC) (The Netherlands)

Sponsor details EMGO-Institute Van der Boechorststraat 7 Amsterdam Netherlands 1081 BT +31 (0)20 444 8180 emgo@vumc.nl

**Sponsor type** Hospital/treatment centre

Website http://www.vumc.nl/english/

ROR https://ror.org/00q6h8f30

## Funder(s)

**Funder type** Research organisation

**Funder Name** European Foundation for the Study of Diabetes (EFSD) (Germany)

**Alternative Name(s)** The European Association for the Study of Diabetes, EFSD

**Funding Body Type** Private sector organisation

**Funding Body Subtype** Trusts, charities, foundations (both public and private)

**Location** Germany

## **Results and Publications**

Publication and dissemination plan

### Not provided at time of registration

### Intention to publish date

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	27/04/2009		Yes	No
Results article	results	01/04/2016		Yes	No
Results article	results	01/04/2016		Yes	No